0.386
Passage Bio Inc (PASG) 最新ニュース
Passage Bio stock plunges to 52-week low of $0.35 By Investing.com - Investing.com South Africa
Passage Bio stock plunges to 52-week low of $0.35 - Investing.com
Layoff Tracker: BioAtla Streamlines Operations By Cutting 30% of Staff - BioSpace
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Krabbe Disease Treatment Market is to grow at a 7.22 % CAGR, with the United States leading the market through 2032 - StreetInsider.com
Strategic Partnership To Advance Gene Therapies For Rare Diseases: Key Trend in The GM1 Gangliosidosis Glob... - WhaTech
Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MyChesCo
Fierce Biotech Layoff Tracker 2025: Elevation eliminates 70% of staff; Vaxart trims team - Fierce Biotech
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Third Arc Bio Enters Clinical Stage with First Patient Dosed in ARC101 Study - MyChesCo
Passage Bio stock plunges to 52-week low of $0.38 amid market challenges - Investing.com Australia
Passage Bio stock plunges to 52-week low of $0.38 amid market challenges By Investing.com - Investing.com South Africa
Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit - MyChesCo
Passage Bio Reports 2024 Financial Results and Advances in PBFT02 Program - MSN
Wedbush Comments on Passage Bio’s Q1 Earnings (NASDAQ:PASG) - Defense World
Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know - Nasdaq
FY2029 Earnings Forecast for Passage Bio Issued By Wedbush - Defense World
Chardan Cuts Price Target on Passage Bio to $6 From $7, Keeps Buy Rating -March 05, 2025 at 07:36 am EST - Marketscreener.com
Passage Bio (NASDAQ:PASG) Price Target Lowered to $6.00 at Chardan Capital - Defense World
Passage Bio Advances Gene Therapy for Neurodegenerative Diseases - TipRanks
Strategic Restructuring and Promising Data Catalysts Drive Buy Rating for Passage Bio - TipRanks
Chardan cuts Passage Bio stock price target to $6, maintains buy - Investing.com India
Chardan cuts Passage Bio stock price target to $6, maintains buy By Investing.com - Investing.com South Africa
Passage Bio stock plunges to 52-week low of $0.45 - Investing.com India
Passage Bio stock plunges to 52-week low of $0.45 By Investing.com - Investing.com South Africa
Passage Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.
PASSAGE BIO, INC. Full Year Loss Decreases - Nasdaq
Passage Bio Reports 2024 Financial Results and Program Advances - TipRanks
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights - The Manila Times
Passage BIO, Inc. SEC 10-K Report - TradingView
Passage Bio reports FY24 EPS ($1.07) vs ($1.86) last year - TipRanks
Passage Bio Reports Fourth Quarter and Full Year 2024 Results -March 04, 2025 at 07:07 am EST - Marketscreener.com
Passage Bio Reports Promising Interim Data for PBFT02 in FTD-GRN Patients and Provides Business Updates - Nasdaq
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent - The Bakersfield Californian
Can Passage Bio's FTD-GRN Treatment Breakthrough Translate to Market Success? - StockTitan
Passage Bio to Present at Two Major Investor Conferences - MSN
Passage Bio (PASG) to Release Quarterly Earnings on Monday - Defense World
Passage Bio to Participate in Upcoming Investor Conferences - GlobeNewswire
Genetic Medicine Pioneer Passage Bio Sets March Investor Conference Schedule - StockTitan
大文字化:
|
ボリューム (24 時間):